On May 17, 2019, a majority of the independent directors of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) recommended to the Board, and a majority of the Board affirmatively approved, that Ashley M. Keating be appointed to fill the Class III vacancy on the Board of the Company, effective May 17, 2019, and that Ms. Keating shall hold such position as a Class III director until the 2022 Annual Meeting of Stockholders and until her successor is duly elected and qualified or until her earlier death, resignation or removal. Ms. Keating has not been, nor is she expected to be, named to any committees of the Board at this time.

Ms. Keating is currently the Chief Financial Officer of CincyTech, one of the most active seed-stage investors in the Midwest focused on providing startup capital and guidance to human health and technology companies primarily in Southwest Ohio. From 2005 to April 2016, Ms. Keating worked at PricewaterhouseCoopers (PwC) where she focused on finance, operations, business leadership and mergers and acquisitions. She began her career in audit services at PwC’s Cincinnati office and later transferred to PwC’s transaction services practice in the New York and London offices. Ms. Keating is a Certified Public Accountant. She received her Bachelor of Business Administration in Accounting and Finance from Ohio University. While at Ohio University Ms. Keating played on the women’s golf team and was named a Division I All-American Scholar.

Ms. Keating will participate in the Company’s standard compensation program for non-employee directors. On May 17, 2019, Ms. Keating was granted an equity award in the form of an option to purchase 6,472 shares of the Company’s common stock with an exercise price equal to the closing price per share of the Company’s common stock on May 17, 2019, the date of the grant, and a term of seven years. The Company expects to enter into the Company’s standard indemnification agreement for directors and officers with Ms. Keating.

About MEDPACE HOLDINGS, INC. (NASDAQ:MEDP)

Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.